Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NASDAQ:INDV NASDAQ:LEGN NASDAQ:MRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$86.16$84.70$16.64▼$96.50$4.71B1.18454,001 shs612,371 shsINDVIndivior$36.76$32.93$11.04▼$41.00$4.48B0.92.38 million shs1.82 million shsLEGNLegend Biotech$27.55$21.29$16.24▼$45.30$5.10B0.292.96 million shs1.80 million shsMRVIMaravai LifeSciences$4.15$3.44$1.95▼$4.99$1.07B0.622.53 million shs1.54 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics0.00%-0.78%-7.61%+81.77%+337.58%INDVIndivior0.00%-6.94%+12.42%+6.30%+224.16%LEGNLegend Biotech0.00%-2.03%+30.14%+56.71%-0.83%MRVIMaravai LifeSciences0.00%-14.43%+22.42%+40.20%+97.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$86.16$84.70$16.64▼$96.50$4.71B1.18454,001 shs612,371 shsINDVIndivior$36.76$32.93$11.04▼$41.00$4.48B0.92.38 million shs1.82 million shsLEGNLegend Biotech$27.55$21.29$16.24▼$45.30$5.10B0.292.96 million shs1.80 million shsMRVIMaravai LifeSciences$4.15$3.44$1.95▼$4.99$1.07B0.622.53 million shs1.54 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics0.00%-0.78%-7.61%+81.77%+337.58%INDVIndivior0.00%-6.94%+12.42%+6.30%+224.16%LEGNLegend Biotech0.00%-2.03%+30.14%+56.71%-0.83%MRVIMaravai LifeSciences0.00%-14.43%+22.42%+40.20%+97.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 3.00Buy$117.8236.74% UpsideINDVIndivior 3.00Buy$39.337.00% UpsideLEGNLegend Biotech 2.67Moderate Buy$59.00114.16% UpsideMRVIMaravai LifeSciences 2.50Moderate Buy$5.5032.53% UpsideCurrent Analyst Ratings BreakdownLatest MRVI, DNTH, LEGN, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.005/13/2026MRVIMaravai LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026LEGNLegend Biotech Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$62.00 ➝ $64.005/13/2026LEGNLegend Biotech TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$29.005/13/2026LEGNLegend Biotech Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$49.00 ➝ $48.005/8/2026MRVIMaravai LifeSciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.005/8/2026MRVIMaravai LifeSciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.50 ➝ $5.505/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/6/2026DNTHDianthus Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$103.00 ➝ $105.004/21/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.00(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$2.04M2,309.00N/AN/A$11.41 per share7.55INDVIndivior$1.24B3.62$2.72 per share13.52($0.78) per share-47.13LEGNLegend Biotech$1.14B4.47N/AN/A$5.43 per share5.07MRVIMaravai LifeSciences$185.74M5.77$0.42 per share9.91$1.46 per share2.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%8/6/2026 (Estimated)INDVIndivior$210M$1.9518.859.99N/A19.44%-219.26%29.40%7/30/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A16.40N/A-21.98%-24.92%-14.87%N/AMRVIMaravai LifeSciences-$130.77M-$0.71N/AN/AN/A-51.07%-17.87%-9.08%N/ALatest MRVI, DNTH, LEGN, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/7/2026Q1 2026MRVIMaravai LifeSciences-$0.05$0.01+$0.06-$0.02$53.00 million$65.84 million5/5/2026Q1 2026DNTHDianthus Therapeutics-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/11/2026Q4 2025LEGNLegend Biotech-$0.17$0.01+$0.18-$0.16$310.21 million$306.30 million3/9/2026Q4 2025DNTHDianthus Therapeutics-$0.97-$1.43-$0.46-$1.43$0.40 million$0.57 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 million2/25/2026Q4 2025MRVIMaravai LifeSciences-$0.07-$0.04+$0.03-$0.24$49.06 million$49.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A29.2529.25INDVIndiviorN/A0.860.66LEGNLegend BiotechN/A2.132.05MRVIMaravai LifeSciences0.725.914.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%INDVIndivior60.33%LEGNLegend Biotech70.89%MRVIMaravai LifeSciences50.25%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics3.02%INDVIndivior0.74%LEGNLegend Biotech0.02%MRVIMaravai LifeSciences2.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8054.67 million53.02 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableLEGNLegend Biotech2,965184.96 million184.92 millionOptionableMRVIMaravai LifeSciences610258.19 million251.76 millionOptionableMRVI, DNTH, LEGN, and INDV HeadlinesRecent News About These CompaniesHow The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 GuidanceMay 16 at 9:52 AM | finance.yahoo.com457,707 Shares in Maravai LifeSciences Holdings, Inc. $MRVI Purchased by Brummer Multi Strategy ABMay 11, 2026 | marketbeat.comMaravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call TranscriptMay 10, 2026 | seekingalpha.comMaravai LifeSciences (NASDAQ:MRVI) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysMay 10, 2026 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Announces Earnings ResultsMay 9, 2026 | marketbeat.comMaravai (MRVI) Q1 2026 Earnings TranscriptMay 9, 2026 | finance.yahoo.comMaravai LifeSciences (NASDAQ:MRVI) Reaches New 1-Year High Following Analyst UpgradeMay 9, 2026 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Reaches New 12-Month High After Analyst UpgradeMay 9, 2026 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Maravai LifeSciences (NASDAQ:MRVI) StockMay 8, 2026 | marketbeat.comMaravai LifeSciences (NASDAQ:MRVI) Shares Gap Up Following Analyst UpgradeMay 8, 2026 | marketbeat.comMaravai LifeSciences Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comMaravai LifeSciences Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comMaravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue EstimatesMay 7, 2026 | zacks.comAll You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to BuyMay 6, 2026 | zacks.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by BrokeragesMay 1, 2026 | marketbeat.comBaxter International (BAX) Tops Q1 Earnings and Revenue EstimatesApril 30, 2026 | zacks.comMaravai LifeSciences (MRVI) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comMaravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)April 30, 2026 | marketbeat.comMaravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026April 21, 2026 | timesargus.comTMaravai LifeSciences (MRVI) carrying moderately bullish sentiment despite options-linked volatilityApril 14, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRVI, DNTH, LEGN, and INDV Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$86.16 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$86.06 -0.10 (-0.12%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Indivior NASDAQ:INDV$36.76 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$36.98 +0.22 (+0.59%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Legend Biotech NASDAQ:LEGN$27.55 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$27.25 -0.30 (-1.09%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Maravai LifeSciences NASDAQ:MRVI$4.15 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$4.22 +0.07 (+1.69%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
